Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/308% above fair value
$955.47+4.28 (+0.45%)
Close on Nov 13, 2026Market cap $98.84BP/E 21.1Yield –
Regeneron Pharmaceuticals price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Regeneron Pharmaceuticals's price to book ratio was 3.2× on Nov 11, 2026, against 2.8× a year earlier. Over the last 5 years it ranged from 1.9× to 4.8×, with a median of 3.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.2× | +0.5 |
| 2025 | Dec 31, 2025 | 2.7× | −0.0 |
| 2024 | Dec 31, 2024 | 2.8× | −1.2 |
| 2023 | Dec 29, 2023 | 4.0× | +0.2 |
| 2022 | Dec 30, 2022 | 3.8× | −0.3 |
| 2021 | Dec 31, 2021 | 4.1× | −1.4 |
| 2020 | Dec 31, 2020 | 5.5× | +1.4 |
| 2019 | Dec 31, 2019 | 4.1× | −1.4 |
| 2018 | Dec 31, 2018 | 5.5× | −1.7 |
| 2017 | Dec 29, 2017 | 7.2× | −2.2 |
| 2016 | Dec 30, 2016 | 9.4× | −9.5 |
| 2015 | Dec 31, 2015 | 18.9× | +1.2 |
| 2014 | Dec 31, 2014 | 17.7× | −1.4 |
| 2013 | Dec 31, 2013 | 19.1× | −0.9 |
| 2012 | Dec 31, 2012 | 20.0× | +8.3 |
| 2011 | Dec 30, 2011 | 11.7× | +4.2 |
| 2010 | Dec 31, 2010 | 7.5× | – |
See a number that looks wrong?